Best Practices in the Management of Advanced Non-Small Cell Lung Cancer (NSCLC): Individualizing Therapy for Optimized Patient Outcomes


A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 11, 2018 to July 31, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca, Merck & Co., and Takeda Oncology

Description:
Lung cancer is the second most common cancer and is by far the leading cause of cancer death among men and women, according to the American Cancer Society. More people die of lung cancer than of colon, breast, and prostate cancers combined. Non small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include targeted agents to individualize treatment for patients with advanced disease. This includes treatment options for patients with EGFR mutation–positive NSCLC. and these options may help increase prognosis and quality of life in NSCLC patients. Molecular testing has now become a critical part of selecting treatment for patients with advanced NSCLC. Nearly two-thirds of NSCLC patients who are EGFR mutation-positive and experience disease progression after being treated with an EGFR-TKI develop a T790M resistance mutation, for which there have been limited treatment options.

Upon Completion of this activity, participants will be able to:

  • Evaluate safety and efficacy profiles of current and emerging treatment options in the management of advanced non-small cell lung cancer (NSCLC)

  • Analyze targeted treatment options for advanced EGFR-mutated NSCLC, during first-line therapy and in the setting of disease progression, focusing on safety, efficacy, and the individualization of therapy based on tumor and patient specific factors

  • Explore recent clinical data and guideline updates on newly approved therapies for the ALK+ advanced NSCLC

  • Analyze management strategies for patients with advanced EGFR-Mutated NSCLC who develop a T790M resistance mutation

  • Discuss the benefits and limitations of immunotherapies in advanced NSCLC

  • Assess strategies for prevention, detection, and optimal management of adverse effects in patients undergoing treatment for advanced NSCLC, to ensure that patients maintain high level quality of life while completing the selected therapy
     

Faculty: David Jackman, MD
Senior Physician, Dana-Farber Cancer Institute
Medical Director of Clinical Pathways, Dana-Farber Cancer Institute
Assistant Professor, Harvard Medical School

Disclosure:

Dr. Jackman serves on an advisory board for AstraZeneca, Celgene and Lilly. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca, Merck & Co., and Takeda Oncology

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue